ABSTRACT
Lipid nanoparticle mRNA vaccines are an exciting but new technology used in humans. There is limited understanding of factors that influence their biodistribution and immunogenicity. Antibodies to polyethylene glycol (PEG), which is on the surface of the lipid nanoparticle, are detectable in humans and boosted by human mRNA vaccination. We hypothesized that PEG-specific antibodies could increase the clearance of mRNA vaccines. We developed methods to quantify both the mRNA and ionizable lipid in frequent serial blood samples from 19 subjects receiving Moderna SPIKEVAX mRNA booster immunization. Both the mRNA and ionizable lipid peaked in blood 1-2 days post vaccination (median peak level 0.19 and 3.22 ng mL-1, respectively). The mRNA was detectable out to 14-28 days post-vaccination in most subjects. We measured the proportion of mRNA that was relatively intact in blood over time and found the decay kinetics of the intact mRNA and ionizable lipid were identical, suggesting the intact lipid nanoparticle recirculates in blood. However, mRNA and ionizable lipid decay rates did not correlate with baseline levels of PEG-specific nor spike-specific antibodies. The magnitude of mRNA and ionizable lipid detected in blood did correlate with the boost in PEG antibodies. Further, the ability of subject’s monocytes to phagocytose lipid nanoparticles had an inverse relationship with the rise in PEG antibodies. This suggests circulation of mRNA lipid nanoparticle vaccines into the blood and their ability to be cleared by phagocytes influence PEG immunogenicity of mRNA vaccines. Overall, this work defines the pharmacokinetics of lipid nanoparticle mRNA vaccine components in human blood after intramuscular injection and the factors that influence this. These insights should prove useful in improving the future safety and efficacy of lipid nanoparticle mRNA vaccines and therapeutics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Australian Research Council (ARC) Discovery Project (DP210103114 to FC, SJK and YJ), the National Health and Medical Research Council (NHMRC) program grant (GNT1149990 to SJK and MPD), the Victorian Critical Vaccinees Collection COVID-19 Research Seed Funding Grant (YJ), an ARC Discovery Early Career Researcher Award (DE230101542 to YJ), and NHMRC Investigator grants (SJK, WSL, GNT2016732 to FC, JAJ, AKW, and MPD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocols were approved by the University of Melbourne human research and ethics committee (approvals #2056689), and all associated procedures were carried out in accordance with the approved guidelines. All participants provided written informed consent in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
